Monoclonal Antibody to Immunoglobulin Superfamily, Member 12 (IGSF12)
| Code | Size | Price |
|---|
| MAB731Mu23-20ul | 20uL | £85.00 |
Quantity:
| MAB731Mu23-100ul | 100ul | £156.00 |
Quantity:
| MAB731Mu23-200ul | 200ul | £210.00 |
Quantity:
| MAB731Mu23-1ml | 1ml | £479.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1 Kappa
Antibody Clonality: Monoclonal
Antibody Clone: C12
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Further Information
Alternative Names:
CD300A; CMRF35H; CMRF35H9; IRC1; IRC2; IRp60; CD300 antigen-like family member A; CMRF35-like molecule 8; Inhibitory receptor protein 60; NK inhibitory receptor
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Immunoglobulin Superfamily, Member 12
Potency (Clone Number):
C12
Reactivity:
Hu;
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Immunoglobulin Superfamily, Member 12 (IGSF12) | RPB731Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||